Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
NeoImmuneTech
Alterome Therapeutics, Inc.
ToLymph Inc.
Hoffmann-La Roche
Nuvectis Pharma, Inc.
AstraZeneca
AstraZeneca
Avenzo Therapeutics, Inc.
Boehringer Ingelheim
Shanghai Pulmonary Hospital, Shanghai, China
AstraZeneca
Pheon Therapeutics
Pheon Therapeutics
Auricula Biosciences Inc.
DualityBio Inc.
Pfizer
Tanabe Pharma America, Inc.
Adaptimmune
Novartis
AstraZeneca
Iovance Biotherapeutics, Inc.
AstraZeneca
AstraZeneca
Sichuan Baili Pharmaceutical Co., Ltd.
Genelux Corporation
Institut Bergonié
Sanofi
Trans Tasman Radiation Oncology Group
University Health Network, Toronto
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
AstraZeneca
Hoffmann-La Roche
Numab Therapeutics AG
Stanford University
Kiromic BioPharma Inc.
Intensity Therapeutics, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Iovance Biotherapeutics, Inc.
Simcha IL-18, Inc.
Cancer Research UK
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
University of Cologne
Advaxis, Inc.
The Central Hospital of Lishui City
R-Pharm
Evopoint Biosciences Inc.